HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
-
REGULATORY Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
-
REGULATORY Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
August 28, 2023
-
REGULATORY MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
August 25, 2023
-
ACADEMIA Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
-
REGULATORY Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
August 24, 2023
-
REGULATORY Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
REGULATORY Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
REGULATORY Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
August 24, 2023
-
REGULATORY Japan Approves Enhertu’s NSCLC Use, More Label Expansions
August 24, 2023
-
REGULATORY Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
August 23, 2023
-
REGULATORY Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
August 23, 2023
-
REGULATORY Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
August 22, 2023
-
REGULATORY MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
August 21, 2023
-
BUSINESS Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
-
BUSINESS Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
August 17, 2023
-
REGULATORY Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
-
BUSINESS Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
August 14, 2023
-
REGULATORY Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
August 10, 2023
-
REGULATORY Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
